(0.31%) 5 107.50 points
(0.70%) 38 651 points
(0.60%) 17 757 points
(-0.01%) $78.94
(0.29%) $2.04
(-0.02%) $2 309.10
(-0.26%) $26.76
(1.48%) $976.80
(-0.15%) $0.931
(-0.52%) $10.93
(-0.21%) $0.796
(0.54%) $91.62
5 days till quarter result
(amc 2024-05-08)
Expected move: +/- 11.19%
-4.98% $ 26.52
@ $38.32
Emitido: 14 feb 2024 @ 15:08
Retorno: -30.79%
Señal anterior: feb 13 - 15:48
Señal anterior:
Retorno: -0.52 %
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
Volumen de hoy | 692 569 |
Volumen promedio | 501 903 |
Capitalización de mercado | 713.79M |
EPS | $0 ( 2024-03-07 ) |
Próxima fecha de ganancias | ( $-1.170 ) 2024-05-08 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -23.68 |
ATR14 | $0.0460 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
2023-12-15 | Sassine Andy | Buy | 75 000 | Employee Stock Option (right to buy) |
2023-12-15 | Chivukula Pad | Buy | 125 000 | Employee Stock Option (right to buy) |
2023-12-15 | Kurata Lance | Buy | 75 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
77.94 |
Last 97 transactions |
Buy: 2 555 134 | Sell: 1 046 972 |
Volumen Correlación
Arcturus Therapeutics Correlación
10 Correlaciones Más Positivas | |
---|---|
AVEO | 0.955 |
ITMR | 0.949 |
RBNC | 0.939 |
HEAR | 0.932 |
SUMR | 0.929 |
FCBP | 0.92 |
DVCR | 0.92 |
RMRM | 0.918 |
EA | 0.917 |
AMYT | 0.917 |
10 Correlaciones Más Negativas | |
---|---|
SBNY | -0.929 |
IMV | -0.925 |
DPRO | -0.92 |
NDRA | -0.913 |
MNDO | -0.91 |
CLDX | -0.909 |
SSPK | -0.909 |
WABC | -0.908 |
DFFN | -0.907 |
TCBC | -0.907 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arcturus Therapeutics Correlación - Moneda/Commodity
Arcturus Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $157.75M |
Beneficio Bruto: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
Ingresos: | $157.75M |
Beneficio Bruto: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
Ingresos: | $205.76M |
Beneficio Bruto: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
Ingresos: | $12.36M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.12 | -- |
Div. Sustainability Score | 1.571 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.165 | 1.500 | -3.31 | -4.96 | [0 - 0.5] |
returnOnAssetsTTM | -0.0619 | 1.200 | -2.06 | -2.48 | [0 - 0.3] |
returnOnEquityTTM | -0.0907 | 1.500 | -2.12 | -3.18 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.62 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.23 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0704 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -92.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.392 | -0.784 | [0 - 20] |
debtEquityRatioTTM | 0.108 | -1.500 | 9.57 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.65 | 7.65 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.442 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.596 | 1.000 | -4.42 | -4.42 | [0.2 - 2] |
assetTurnoverTTM | 0.375 | 0.800 | -0.836 | -0.668 | [0.5 - 2] |
Total Score | 1.571 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -26.56 | 1.000 | -2.78 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0907 | 2.50 | -1.362 | -3.18 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.261 | -0.784 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.443 | 1.500 | -6.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.112 | 1.000 | -5.30 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico